Pardo Geoffrey B 4
4 · SpyGlass Pharma, Inc. · Filed Feb 9, 2026
Research Summary
AI-generated summary of this filing
SpyGlass Pharma (SGP) Director Geoffrey Pardo Receives 27,400-Share Award
What Happened
Geoffrey B. Pardo, a director of SpyGlass Pharma, received a grant of 27,400 derivative shares on Feb 5, 2026. The award shows a $0.00 acquisition price (i.e., no cash paid). This is a compensation award (not an open-market purchase or sale).
Key Details
- Transaction date: February 5, 2026; Form 4 filed February 9, 2026 (timely filing).
- Shares granted: 27,400 derivative shares; reported acquisition price: $0.00.
- Shares owned after transaction: Not disclosed in this filing.
- Vesting footnote: Award vests monthly over 36 months — 1/36th each month starting on the grant date (Feb 5, 2026) — contingent on Pardo continuing as an Outside Director under the issuer’s 2026 Equity Incentive Plan (Footnote F1).
- Transaction type code: A = Award/Grant (derivative securities).
Context This grant appears to be board compensation that vests over three years rather than an immediate market purchase or sale. Because the award vests monthly, the director will not have full ownership until vesting occurs and any further filings (e.g., sales or exercises) would show if/when shares become tradable.
Insider Transaction Report
Form 4
Pardo Geoffrey B
Director
Transactions
- Award
Stock Option (right to buy)
[F1]2026-02-05+27,400→ 27,400 totalExercise: $16.00Exp: 2036-02-05→ Common Stock (27,400 underlying)
Footnotes (1)
- [F1]Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2026 Equity Incentive Plan) through such applicable vesting date, one thirty-sixth (1/36th) of the shares subject to the option shall vest each month following the Date of Grant on the same day of the month as the Date of Grant (and if there is no corresponding day, on the last day of the month). "Date of Grant" shall mean February 5, 2026.
Signature
/s/ Brian Aukshunas, as Attorney-in-Fact|2026-02-09